HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $20 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on ATAI Life Sciences (NASDAQ:ATAI) and maintained a $20 price target.
August 14, 2023 | 10:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ATAI Life Sciences has received a reiterated 'Buy' rating and a maintained price target of $20 from HC Wainwright & Co.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for ATAI Life Sciences. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100